P1381Improved outcome in ablation of ventricular tachycardia in patients with structural heart disease under general anaesthetic

Autor:	Claire A. Martin, B Di Nubila, R Y Zhang, K Divulwewa, Ibrahim T. Fazmin, David Begley, Munmohan Virdee, A Porto, Sharad Agarwal, Andrew A. Grace, Simon P. Fynn, M F Mausa, Greg Mellor, Patrick M. Heck, A Reddy
Rok vydání:	2020
Předmět:	medicine.medical_specialty Heart disease business.industry medicine.medical_treatment Ablation Ventricular tachycardia medicine.disease Physiology (medical) Internal medicine medicine Cardiology In patient Cardiology and Cardiovascular Medicine General anaesthetic business
Zdroj:	EP Europace. 22
ISSN:	1532-2092 1099-5129
DOI:	10.1093/europace/euaa162.007
Popis:	Background Catheter ablation is an important adjunct to device implantation for secondary prevention of ventricular tachycardia (VT). However, several factors may influence the success of ablations in terms of long-term freedom from VT recurrence. A thus far little examined factor is the use of general anaesthetic (GA) versus conscious sedation during the procedure, which has been shown to improve outcomes in persistent atrial fibrillation (AF) ablation. Methods Patients with structural heart disease VT undergoing ablations from January 2015 to March 2019 were retrospectively followed up at a single centre. End points were recurrent VT or device therapy (shock or anti-tachycardia pacing) at one year. Hazard ratios (HR) were generated using a multivariate Cox-regression proportional hazards model including variables of age at ablation, sex, amiodarone use at time of ablation, scar age, left ventricular ejection fraction, use of GA, and diagnosis of: diabetes mellitus (DM), hypertension (HTN), renal impairment or AF. Results 79 patients (74 male, mean age 68.2+/- 10.3 years) were included. A substrate-based strategy of late potential ablation was employed. 69 had ischaemic and 10 had non-ischaemic cardiomyopathy. Mean scar age was 13.8 +/- 9.8 years; EF was 40-50% in 27 patients, 30-40% in 26 and < 30% in 26. 37 patients had implantable cardioverter defibrillators and 30 had cardiac resynchronisation therapy (CRT) defibrillator devices, 1 had a CRT- pacemaker device and 4 had dual chamber pacemakers. Comorbidities were: DM (16), HTN (31), renal impairment (13), AF (31). 62 patients (79.5%) were on amiodarone at the time of ablation. Mean procedure duration was 234.8 +/- 44.5 min and mean radiofrequency energy application time was 2247 +/- 862 s. 61 were first procedures and 18 were repeat procedures. One patient suffered a complication of groin haematoma. 62 patients (78.5%) underwent VT ablation under GA and 17 (21.5%) under sedation of midazolam and fentanyl. Patient characteristics did not differ between groups. Significant factors which increased freedom from VT recurrence or device therapy were HTN (88.9% vs 59.4%, HR 0.72, 95% confidence interval (CI): 0.007-0.75, p= 0.028), amiodarone treatment (50.0% vs 76.3%, HR 0.036, 95% CI: 0.003-0.404, p = 0.036) and ablation under GA rather than sedation (50.0% vs 75.0%, HR 0.055, 95% CI: 0.006-0.495, p = 0.01) (Fig 1). Conclusions In patients with structural heart disease undergoing VT ablation, outcomes are improved with the use of GA over conscious sedation. Abstract Figure 1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ad7d1cecf8282150273ba8ee96a041e2 https://doi.org/10.1093/europace/euaa162.007 Zobrazit plný text záznamu